ArticleTranslational lung cancer research2025
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hematopoietic Aging and Leukemia: Mechanistic and Therapeutic Insights.International journal of molecular sciences · 2026Review
- Bridging FDA Adverse Event Reporting System (FAERS) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients.Thoracic cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dual immune checkpoint inhibitor (ICI) therapy with nivolumab plus ipilimumab (NIVO + IPI) has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC). Although immune-related adverse events (irAEs) have been linked to improved outcomes, this relationship remains unclear in elderly patients, who may be more vulnerable to toxicity. This study aimed to evaluate the efficacy and safety of NIVO + IPI in elderly patients with advanced NSCLC and to explore the prognostic value of early irAEs. Methods: We conducted a retrospective study to evaluate the efficacy, safety, and prognostic significance of early irAEs in elderly NSCLC patients receiving NIVO + IPI. Patients aged ≥75 years who initiated NIVO + IPI between February 2021 and October 2023 were included. Data collection concluded in February 2025. Treatment responses, irAE profiles, and survival outcomes were assessed. A 6-week landmark analysis was performed to evaluate the prognostic impact of early irAEs. Results: Twenty-seven patients were included (median age, 80 years). The objective response rate was 22.2%, and the disease control rate was 62.9%. Median progression-free survival (PFS) and overall survival (OS) were 6.5 and 13.0 months, respectively. Fifteen patients (55.6%) developed irAEs, most commonly skin rash (n=8), interstitial lung disease (ILD; n=4), and colitis (n=4). All ILD cases were grade ≥3, including one treatment-related death. In the 6-week landmark analysis, early irAE occurrence was associated with longer survival: median OS was 26.4 Conclusions: NIVO + IPI is a feasible and effective treatment option for selected elderly patients with advanced NSCLC. Early irAE development may serve as a favorable prognostic marker. However, the high frequency of grade ≥3 ILD highlights the importance of early recognition, timely management, and efforts to predict ILD onset in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.